BTIG Research began coverage on shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in a research report sent to investors on Friday, July 21st, MarketBeat.com reports. The firm issued a buy rating and a $36.00 price objective on the stock.
Several other equities analysts have also recently weighed in on the stock. BMO Capital Markets raised their price target on shares of Protagonist Therapeutics from $34.00 to $45.00 and gave the company an outperform rating in a research report on Wednesday, May 31st. Zacks Investment Research raised shares of Protagonist Therapeutics from a sell rating to a hold rating in a research report on Wednesday, May 10th. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and a consensus price target of $26.00.
Protagonist Therapeutics (NASDAQ PTGX) traded down 2.78% during mid-day trading on Friday, reaching $11.91. The company had a trading volume of 60,285 shares. Protagonist Therapeutics has a one year low of $8.00 and a one year high of $26.36. The stock has a 50 day moving average price of $12.28 and a 200 day moving average price of $12.30. The company’s market capitalization is $201.30 million.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, August 8th. The company reported ($0.89) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.70.
In related news, insider David Y. Liu sold 3,500 shares of the firm’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $12.68, for a total value of $44,380.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
A number of institutional investors have recently made changes to their positions in PTGX. California State Teachers Retirement System boosted its position in Protagonist Therapeutics by 8.5% in the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after buying an additional 1,300 shares in the last quarter. State Street Corp boosted its position in Protagonist Therapeutics by 20.9% in the second quarter. State Street Corp now owns 112,474 shares of the company’s stock valued at $1,270,000 after buying an additional 19,411 shares in the last quarter. Senzar Asset Management LLC purchased a new position in Protagonist Therapeutics during the second quarter valued at approximately $3,094,000. FMR LLC boosted its position in Protagonist Therapeutics by 0.4% in the second quarter. FMR LLC now owns 2,528,462 shares of the company’s stock valued at $28,597,000 after buying an additional 10,264 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Protagonist Therapeutics by 3.8% in the second quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock valued at $3,680,000 after buying an additional 11,881 shares in the last quarter. 47.46% of the stock is currently owned by institutional investors and hedge funds.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.